smoking weed on glp 1 GLP-1 medications get at the heart of addiction: study – WashU Medicine IUPHAR review – Glucagon-like peptide-1

28, 2025, semaglutide (Ozempic) received FDA approval to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease) and death due to cardiovascular disease in adults with type 2 diabetes (T2DM) and chronic kidney disease (CKD)

Clean ingredients: No artificial flavors, colors, or common allergens

The behavioral effects on eating are well-documented in clinical literature: Dramatically reduced portion sizes: Clinical trials show semaglutide users lose an average of 1315% of body weight and tirzepatide users 1722%, driven largely by significant reductions in portion size and overall food intake

Signs include visible contaminants, unusual smell, or any doubt about sterility